A controlled porosity osmotic pump system with biphasic release of theophylline

被引:10
作者
Bi, Yueqi [1 ,2 ]
Mao, Shengjun [1 ]
Gan, Liangchun [1 ]
Li, Yuanbo [1 ]
Wang, Changguang [1 ]
Xu, Nannan [1 ]
Zheng, Yu [1 ]
Cheng, Qiuhong [1 ]
Hou, Shixiang [1 ]
机构
[1] Sichuan Univ, W China Pharm Sch, Chengdu 610041, Peoples R China
[2] Sichuan Acad Chinese Med Sci, Chengdu 610041, Peoples R China
关键词
controlled porosity osmotic pump; biphasic release; theophylline; nocturnal asthma therapy; drug release mechanism;
D O I
10.1248/cpb.55.1574
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A controlled porosity osmotic pump system with biphasic release of theophylline was developed for the nocturnal therapy of asthma. The developed system was composed of a tablet-in-tablet (TNT) core and a controlled porosity coating membrane. Release pattern of the developed system was influenced by amount of pore former (18.2-45.5%, w/w of polymer), weight gain (16-26 mg per tablet) of the coating membrane and osmotic agents used in inner layer of the TNT core. When sodium phosphate and sodium chloride were selected as the osmotic agents in inner and outer layer of the TNT core respectively, target release profile was obtained with coating solution cellulose acetate-polyethylene glycol 400-diethyl phthallate (54.5-36.4-9.1%, w/w) at a weight gain of 1622 mg per tablet. To examine the mechanism of drug release, release profiles of osmotic agents, micro-environmental osmotic pressure and micro-environmental pH of the formulation during dissolution were studied. Micro-environmental osmotic pressure decreased and micro-environmental pH increased continuously during the whole dissolution process, theophylline release was dominated by the successive dissolution of sodium chloride and sodium phosphate. Theophylline solubility increased as environmental pH exceeded 10.8. At the last stage of the biphasic release, micro-environmental pH in the developed formulation reached 10.9, and theophylline release was promoted by its elevated solubility despite of the decrease of micro-environmental osmotic pressure in the developed formulaiton.
引用
收藏
页码:1574 / 1580
页数:7
相关论文
共 24 条
[1]   Chronopharmacokinetics - Current status [J].
Bruguerolle, B .
CLINICAL PHARMACOKINETICS, 1998, 35 (02) :83-94
[2]  
Burioka N, 2001, BIOMED PHARMACOTHER, V55, p142S
[3]  
Bussemer T, 2001, CRIT REV THER DRUG, V18, P433
[4]   A new oral erosion controlled drug delivery system with a late burst in the release profile [J].
Freichel, OL ;
Lippold, BC .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 50 (03) :345-351
[5]   A unique dosage form to evaluate the mechanical destructive force in the gastrointestinal tract [J].
Kamba, M ;
Seta, Y ;
Kusai, A ;
Ikeda, M ;
Nishimura, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 208 (1-2) :61-70
[6]   Evaluation of the mechanical destructive force in the stomach of dog [J].
Kamba, M ;
Seta, Y ;
Kusai, A ;
Nishimura, K .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2001, 228 (1-2) :209-217
[7]  
KRAFT M, 1995, DIS MON, V41, P501
[8]   The clinical relevance of chronopharmacology in therapeutics [J].
Lemmer, B .
PHARMACOLOGICAL RESEARCH, 1996, 33 (02) :107-115
[9]   Chronopharmacokinetics: Implications for drug treatment [J].
Lemmer, B .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1999, 51 (08) :887-890
[10]   Modulation of combined-release behaviors from a novel "tablets-in-capsule system" [J].
Li, YH ;
Zhu, JB .
JOURNAL OF CONTROLLED RELEASE, 2004, 95 (03) :381-389